lly glp 1 drug Eli Lilly (LLY): GLP-1 Dominance, AI Discovery Lilly launches GLP-1 pill, kicking
Description
& Malagelada, J
Developed by Altimmune
GLP-1 drugs have become a game-changer in treating obesity and type 2 diabetes, forecast to reach a $100 billion market value by 2030
BP-Lowering Effect: The American Diabetes Association (ADA) recommends tight glycemic control and BP reduction to help prevent chronic kidney disease (CKD) in patients with diabetes
This Gs-biased profile may contribute to sustained receptor signaling with less desensitization, though the clinical implications of signaling bias in GLP-1 therapeutics remain an area of active investigation
